drugset / Trial / NCT01818687
Safety and Tolerability Study of MCI-196
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety and tolerability of colestilan (MCI-196) in paediatric subjects (aged 2 years to \<18 years) with CKD stages 3b to 5, diagnosed with hyperphosphataemia, who are not on dialysis.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COLESTILAN CHLORIDE | Other / unclassified | 3 g | — |
| Subject | COLESTILAN CHLORIDE | Other / unclassified | 6 g | — |
| Subject | COLESTILAN CHLORIDE | Other / unclassified | 9 g | — |
| Subject | COLESTILAN CHLORIDE | Other / unclassified | 12 g | — |
| Subject | COLESTILAN CHLORIDE | Other / unclassified | 15 g | — |